One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages

Retinal angiomatous proliferation (RAP) has been known as a variant of exudative age-related macular degeneration (AMD) with a unfavorable prognosis. To evaluate the effect of ranibizumab administered initially as three loading doses for patients with various stages of RAP. A retrospective chart rev...

Full description

Saved in:
Bibliographic Details
Published in:BMC ophthalmology 2015-12, Vol.15 (162), p.182-182, Article 182
Main Authors: Park, Young Gun, Roh, Young-Jung
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Analysis
Angiogenesis Inhibitors - therapeutic use
Care and treatment
Cell proliferation
Complications and side effects
Concert reviews
Concerts
Exudates and Transudates
Female
Fluorescein Angiography
Follow-Up Studies
Health aspects
Humans
Intravitreal Injections
Macular degeneration
Male
Middle Aged
Ophthalmology
Ranibizumab - therapeutic use
Recurrence
Retinal Neovascularization - diagnosis
Retinal Neovascularization - drug therapy
Retreatment
Retrospective Studies
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity - drug effects
Wet Macular Degeneration - diagnosis
Wet Macular Degeneration - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Retinal angiomatous proliferation (RAP) has been known as a variant of exudative age-related macular degeneration (AMD) with a unfavorable prognosis. To evaluate the effect of ranibizumab administered initially as three loading doses for patients with various stages of RAP. A retrospective chart review of 40 patients (41 eyes) with RAP was conducted. The study divided patients into three groups of Group I (8 eyes in stage I), Group II (17eyes in stage II), and Group III (16 eyes in stage III). All patients received three initial monthly intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12 months. Reinjection of ranibizumab after three initial monthly doses was administered on as-needed basis. The main outcome measures were the change in the mean of best-corrected Snellen visual acuity (BCVA) and central macular thickness (CMT), and the total number of injections received during the 12 months. The mean change in BCVA at 12 months was-0.286,-0.165, and-0.151 (logMAR) in Group I, II, and III, respectively. CMT was also reduced by a mean of 32.72 ± 56.75, 57.45 ± 56.48 and 148.37 ± 98.59 μm. The mean number of injections in Group I was significant lower than those in Group II and III (P 
ISSN:1471-2415
1471-2415
DOI:10.1186/s12886-015-0172-2